Heart failure drug verquvo under Real-World watch in korea
NCT ID NCT06148935
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study monitors the safety and effectiveness of Verquvo in 1,350 Korean adults with chronic heart failure with reduced ejection fraction. Participants take Verquvo as prescribed by their doctor, and researchers collect data on side effects, hospital stays, and deaths over up to 12 months. The goal is to see how the drug works in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many Locations
RECRUITINGMultiple Locations, South Korea
Conditions
Explore the condition pages connected to this study.